Zobrazeno 1 - 10
of 249
pro vyhledávání: '"Yasuhide Miyoshi"'
Autor:
Takashi Kawahara, Yusuke Saigusa, Shuko Yoneyama, Masashi Kato, Ippei Kojima, Hiroshi Yamada, Osamu Kamihira, Kenichi Tabata, Hideyasu Tsumura, Masatsugu Iwamura, Kazuhide Makiyama, Hiroji Uemura, Yasuhide Miyoshi
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Despite the widespread availability of medication choices for metastatic castration-resistant prostate cancer (mCRPC), biomarkers to predict the efficacy of each mCRPC treatment have not yet been established. This study developed
Externí odkaz:
https://doaj.org/article/e430379ed3d84f21a810e96d3660a2e6
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background There is no consensus on the role of serum dehydroepiandrosterone (DHEA) concentrations in the detection of prostate cancer. This study examined the effectiveness of serum DHEA in predicting candidate patients for active surveilla
Externí odkaz:
https://doaj.org/article/2d0306542fd4457686688664c2ef959e
Autor:
Yasuhide Miyoshi, Masato Yasui, Shuko Yoneyama, Takashi Kawahara, Yoshihiro Nakagami, Yoshimasa Ohno, Junpei Iizuka, Kazunari Tanabe, Yasunobu Hashimoto, Hideyasu Tsumura, Ken‐ichi Tabata, Masatsugu Iwamura, Akihiro Yano, Satoru Kawakami, Hiroji Uemura
Publikováno v:
BJUI Compass, Vol 2, Iss 2, Pp 105-114 (2021)
Abstract Objectives To evaluate the prognosis of newly diagnosed patients with metastatic hormone‐naïve prostate cancer (mHNPC) and develop a novel prognostic model based on ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Exten
Externí odkaz:
https://doaj.org/article/60cdebd508bd42fe81ffc6b57b74c973
Autor:
Genta Iwamoto, Takashi Kawahara, Yumiko Yokomizo, Yasuhide Miyoshi, Masahiro Yao, Hiroji Uemura
Publikováno v:
Asian Journal of Urology, Vol 8, Iss 3, Pp 332-334 (2021)
Externí odkaz:
https://doaj.org/article/4a4f4418f7b84c548f994db11076f618
Autor:
Kohei Hashimoto, Yasuhide Miyoshi, Tetsuya Shindo, Masakazu Hori, Yasumasa Tsuboi, Ko Kobayashi, Fumimasa Fukuta, Toshiaki Tanaka, Shintaro Miyamoto, Takeshi Maehana, Manabu Okada, Naotaka Nishiyama, Masahiro Yanase, Ryuichi Kato, Hiroshi Hotta, Yasuharu Kunishima, Atsushi Takahashi, Shiro Hinotsu, Koh‐ichi Sakata, Hiroshi Kitamura, Hiroji Uemura, Naoya Masumori
Publikováno v:
Cancer Medicine, Vol 9, Iss 22, Pp 8579-8588 (2020)
Abstract Background To best employ radium‐223 dichloride (Ra‐223) for patients with castration‐resistant prostate cancer (CRPC) and bone metastasis, we investigated the bone‐predominant status in patients treated with Ra‐223. Methods We ret
Externí odkaz:
https://doaj.org/article/2097f250a7eb442e825c4804a5c9ed56
Autor:
Takashi Kawahara, Masashi Kato, Kenichi Tabata, Ippei Kojima, Hiroshi Yamada, Osamu Kamihira, Hideyasu Tsumura, Masatsugu Iwamura, Hiroji Uemura, Yasuhide Miyoshi
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Inflammatory cytokine markers, including the neutrophil-to-lymphocyte ratio (NLR), monocyte-lymphocyte ratio, and platelet-to-lymphocyte ratio, play important roles as prognostic markers in several solid malignancies, including pr
Externí odkaz:
https://doaj.org/article/a9358af53ec44cd4a1723303356d04d8
Publikováno v:
BMC Urology, Vol 20, Iss 1, Pp 1-6 (2020)
Abstract Background Metastatic spinal cord compression (MSCC) from prostate cancer (PC) influences not only patients’ prognosis but also their quality of life. However, little is known about the clinical outcome of surgery for MSCC from PC. We eval
Externí odkaz:
https://doaj.org/article/833e9b68f2594ceab81c285503d0bd20
Autor:
Hiroyoshi Suzuki, Hiroji Uemura, Atsushi Mizokami, Narihiko Hayashi, Yasuhide Miyoshi, Satoshi Nagamori, Yutaka Enomoto, Hideyuki Akaza, Takayuki Asato, Tadayuki Kitagawa, Kazuhiro Suzuki
Publikováno v:
Cancer Medicine, Vol 8, Iss 13, Pp 5891-5902 (2019)
Abstract This open‐label, phase I dose‐finding study evaluated the gonadotropin‐releasing hormone antagonist, TAK‐385, in Japanese patients with nonmetastatic prostate cancer. In a two‐part design, patients received daily oral TAK‐385 at
Externí odkaz:
https://doaj.org/article/d73133c273584c7b9fe91120d5bba7e5
A Case of Switching from GnRH Agonist to Antagonist for Castration Resistant Prostate Cancer Control
Autor:
Rumiko Sugimura, Takashi Kawahara, Yasuhide Miyoshi, Masahiro Yao, Sawako Chiba, Hiroji Uemura
Publikováno v:
Case Reports in Oncology, Vol 12, Iss 3, Pp 688-692 (2019)
GnRH antagonist and GnRH agonist are widely used as androgen deprivation therapy for metastatic prostate cancer. A previous report demonstrated that patients with PSA levels of >20 ng/mL using GnRH antagonists showed favorable outcomes in comparison
Externí odkaz:
https://doaj.org/article/7b1fa1f5233c41ec831f4e494e642feb
Publikováno v:
Case Reports in Oncology, Vol 12, Iss 2, Pp 608-612 (2019)
Introduction: Nivolumab has been introduced for metastatic renal cell carcinoma (mRCC) as a second-line therapy for years. However, despite widespread evidence of its utility, few reports have described the efficacy of nivolumab for mRCC patients on
Externí odkaz:
https://doaj.org/article/53a3ac16593743789f5314f9d4a34bc5